Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Oscar Health Inc (OSCR) Price & Performance

Amylx Pharmaceuticals IncTrade
Oscar Health IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Oscar Health Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.98 (market cap $2.64B), while Oscar Health Inc trades at $28.7 (market cap $8.63B). The key difference: Oscar Health Inc is far larger — about 3.3× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Oscar Health Inc nearer its low. Which is the better fit depends on your goals.

AMLXOSCR
Market Cap
$2.64B$8.63B
Sector
HealthHealth
52-Week High
$24.19$32.18
52-Week Low
$7.82$10.85
Enterprise Value
$2.39B$4.99B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Oscar Health Inc

OSCR trades at $27.97, up 1.08% today, with a bearish technical signal but strong recent earnings beats in Q1 and Q2 2026. The company reported record profitability and raised its full-year outlook, driven by membership growth and cost controls. Key support lies at $26, with resistance at $28. Revenue surged 70% year-over-year in H1 2026 to $4.9 billion, per PYMNTS on August 6, 2026.

Outlook is positive due to robust growth and margin expansion, but risks include execution challenges and competitive pressures. Analysts have a consensus price target of $32.50, with 27% buy ratings. The stock offers value with a P/S of 0.53, though net income volatility remains a concern.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Oscar Health Inc

Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.

Read more on OSCR